Dennis G. Podlesak
Independent ChairmanMr. Dennis G. Podlesak, MBA, serves as Chairman of the Board at Adastra Pharmaceuticals Inc. (formerly known as Tragara Pharmaceuticals, Inc.). Mr. Podlesak is an Executive Chairman at Exalys Therapeutics, Inc. Mr. Podlesak is Venture Partner at Domain Associates, L.L.C. He was a Partner at the firm since November 2007 till January 2020. Mr. Podlesak joined Domain Associates in November 2007 and is an active investor and a founder of a number of Domain companies. He has been Advisor to CEO and Board of Directors at Abyrx, Inc. since December 2018. He serves as Chief Executive Officer or Executive Chairman for a number of Domain's companies resulting in multiple successful exits, intial public offerings and new drug approvals to address unmet medical needs. He served as the President and Chief Executive Officer of Peninsula Pharmaceuticals Inc. since September 14, 2004 and after building it, he led the sale of it to Johnson and Johnson. Mr. Podlesak was a founder and the President and Chief Executive Officer of Cerexa, Inc. and led the sale of Cerexa to Forest Laboratories. In his next role, he was again a founder and the Chief Executive Officer of Calixa Therapeutics, Inc. and successfully led the growth and sale of Calixa to Cubist Pharmaceuticals. Mr. Podlesak also served as the Executive Chairman of Corthera and after repositioning the company, actively participated in the sale of it to Novartis AG. Previously, he served at Peninsula, where he was a Senior Vice President and Head of a North American Business Unit and Global Leadership Team. Mr. Podlesak served in that capacity from February 2003 to August 2004, when that business unit was merged into another unit for strategic reasons. He was recruited to Novartis to strategically reposition and reengineer the North American Business Unit. Before this, Mr. Podlesak was a Vice President and Head of the CEC Division of Allergan and Member of the North American and Global Management Team from July 1998 to October 2002. In that role, he drove the revitalization and dramatic growth in revenue and profitability of the division and several of its leading brands. Mr. Podlesak was also a Vice President and Corporate Officer at PCG. Prior to this role, he spent many years of his career with SmithKline Beecham, where Mr. Podlesak was promoted eight times to positions of increasing responsibility during his tenure. He serves as the Chairman of Adynxx Inc. He serves as Director of Adynxx, Inc. since May 3, 2019. He served as the Chairman of the Board at Tobira Therapeutics, Inc. until November 1, 2016 and its Director from December 2007 to November 1, 2016. He has been the Chairman of Syndax Pharmaceuticals, Inc. since December 2008. He served as the Chairman of the Board at Corthera Inc. since January 2008. He served as the Chairman at Regado Biosciences, Inc., since November 2007. Mr. Podlesak serves as a Director of DRI Holdings, Calixa Therapeutics, Inc., and RightCare Solutions, Inc. He is a Board Observer at Ascenta Therapeutics and Asmacure. He served as a Director of Peninsula Pharmaceuticals Inc., since September 14, 2004 until June 2005. He served as an Independent Director of Avanir Pharmaceuticals, Inc. from March 17, 2005 to January 13, 2015. He served as a Director of Cerexa, Inc. He served as an Independent Director of DOV Pharmaceutical Inc., since April 4, 2006. Mr. Podlesak is a Board member of Kalidex Pharmaceuticals. He is active on a number of industry boards and serves on the Board of Directors of Prevent Blindness. Mr. Podlesak has many years of strategic, operational and commercial experience within the pharmaceutical industry and a track record of success growing companies and leading business development and licensing, financing and merger and acquisition initiatives. Mr. Podlesak earned an M.B.A. from Pepperdine University in 1990, completed Post Graduate Studies from The Wharton School, University of Pennsylvania and a B.A. Degree in Business Administration from Western Illinois University in 1979. Mr. Podlesak is the Chief Executive Officer and Managing Partner of Canaan Partners’ Axceliux LLC.
Positions
- Company NameSyndax Pharmaceuticals, Inc.Stock CodeSNDXPositionIndependent ChairmanColleagues
- MAMichael A. MetzgerCEO & Director
- LJLuke J. AlbrechtGeneral Counsel & Corporate Secretary
- KAKeith Alan GoldanExecutive Officer
- SCSteven ClosterChief Commercial Officer
- NANicholas A.J. BotwoodHead of Research & Development and Chief Medical Officer
- PLPierre LegaultIndependent Director
- KAKeith A. KatkinIndependent Director
- JAJennifer A. JarrettIndependent Director
